Active substance
Results for the substance avacopan
1 result
About this active substance
Avacopan is a C5a receptor inhibitor used in the treatment of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, a rare autoimmune disease affecting small and medium-sized blood vessels. It works by blocking the activity of the complement fragment C5a, reducing inflammation and preventing tissue damage.
Avacopan is administered orally, usually once daily, and is used in combination with other immunosuppressive therapies such as corticosteroids or cytotoxic agents. It is indicated for patients with active ANCA-associated vasculitis, helping to reduce disease activity and prevent relapses.
Common side effects include nausea, headache, fatigue, and respiratory infections. In rare cases, severe adverse reactions such as serious infections or allergic reactions may occur. Regular monitoring of hematological parameters and renal function is essential during treatment.
Avacopan represents an innovative therapeutic option for patients with ANCA-associated vasculitis, offering a targeted approach to controlling inflammation and improving quality of life.
Avacopan is administered orally, usually once daily, and is used in combination with other immunosuppressive therapies such as corticosteroids or cytotoxic agents. It is indicated for patients with active ANCA-associated vasculitis, helping to reduce disease activity and prevent relapses.
Common side effects include nausea, headache, fatigue, and respiratory infections. In rare cases, severe adverse reactions such as serious infections or allergic reactions may occur. Regular monitoring of hematological parameters and renal function is essential during treatment.
Avacopan represents an innovative therapeutic option for patients with ANCA-associated vasculitis, offering a targeted approach to controlling inflammation and improving quality of life.